Displaying drugs 11176 - 11200 of 11952 in total
DSP107
DSP107 is a bi-functional, trimeric, fusion protein composed of sequences from the extracellular domain of SIRPα and 4-1BBL.
Investigational
Matched Description: … DSP107 is a bi-functional, trimeric, fusion protein composed of sequences from the extracellular domain …
SerpinPC
SerpinPC is a mutated alpha-1-antitrypsin (α1AT) and serine protease inhibitor being investigated for the treatment of hemophilia.
Investigational
Matched Description: … SerpinPC is a mutated alpha-1-antitrypsin (α1AT) and serine protease inhibitor being investigated for …
PNT001
PNT001 is a humanized IgG4 S228P monoclonal antibody targeting the cis conformation of the phosphorylated Thr231-Pro232 motif in tau.
Investigational
Matched Description: … PNT001 is a humanized IgG4 S228P monoclonal antibody targeting the cis conformation of the phosphorylated …
TRK-250
TRK-250 is a small interfering RNA agent that targets human transforming growth factor-beta 1 (TGF-β1) messenger RNA.
Investigational
Matched Description: … TRK-250 is a small interfering RNA agent that targets human transforming growth factor-beta 1 (TGF-β1 …
Rindopepimut
Rindopepimut (CDX-110) is an injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases. The vaccine consists of the EGFRv3-specific peptide (a 13-amino acid mutant vIII epitope) conjugated to the non-specific immunomodulator keyhole limpet hemocyanin (KLH). The US FDA granted...
Investigational
Matched Description: … Rindopepimut (CDX-110) is an injectable peptide cancer vaccine which targets a mutant protein called ... The vaccine consists of the EGFRv3-specific peptide (a 13-amino acid mutant vIII epitope) conjugated …
G207
G207 is cancer-killing viruses, so-called oncolytic viruses, for the treatment of various forms of cancer developed by MediGene AG. These viruses are specific herpes simplex viruses, or HSVs, generally known as the cause of cold sores. MediGene uses these viruses, however, in a modified and "disarmed" form in order to...
Investigational
Matched Description: … as a therapeutic agent in humans. ... MediGene uses these viruses, however, in a modified and "disarmed" form in order to make them utilizable …
Velafermin
Velafermin was a novel investigational protein therapeutic, also known as fibroblast growth factor-20 (FGF-20), which promotes both epithelial and mesenchymal cell proliferation in vitro and has demonstrated activity in multiple animal models. Velafermin was investigated as a potential therapy for the prevention and treatment of oral mucositis by fostering the...
Investigational
Matched Description: … Velafermin was a novel investigational protein therapeutic, also known as fibroblast growth factor-20 ... Velafermin was investigated as a potential therapy for the prevention and treatment of oral mucositis …
Candoxatrilat
A dicarboxylic acid monoamide obtained by formal condensation between the amino group of cis-4-aminocyclohexanecarboxylic acid and the cyclopentanecarboxylic acid group of 1-[(2S)-2-carboxy-3-(2-methoxyethoxy)propyl]cyclopentanecarboxylic acid. A potent inhibitor of neutral endopeptidase (NEP, neprilysin, EC 3.4.24.11), it is used as its 2,3-dihydro-1H-inden-5-yl ester prodrug in the treatment of chronic heart failure.
Experimental
Matched Description: … A potent inhibitor of neutral endopeptidase (NEP, neprilysin, EC 3.4.24.11), it is used as its 2,3-dihydro ... A dicarboxylic acid monoamide obtained by formal condensation between the amino group of cis-4-aminocyclohexanecarboxylic …
Erythroxylum catuaba bark
"Catuaba" is a general term for a medicinal infusion created by the bark of plants belonging to the Erythroxylum genus, though this name is also applied to infusions of plants belonging to other genera. The infusion is thought to carry stimulant and aphrodisiac effects, and catuaba made specifically with Trichilia...
Experimental
Matched Description: … "Catuaba" is a general term for a medicinal infusion created by the bark of plants belonging to the _ …
Tenalisib
Tenalisib is under investigation in clinical trial NCT03711604 (Compassionate Use Study of Tenalisib (RP6530)).
Investigational
Galegenimab
Galegenimab is under investigation in clinical trial NCT03972709 (A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration (AMD)).
Investigational
Matched Description: … Galegenimab is under investigation in clinical trial NCT03972709 (A Study Assessing the Safety, Tolerability …
Stapokibart
Stapokibart is under investigation in clinical trial NCT06424470 (Study on the Treatment of Prurigo Nodularis With Stapokibart Injection).
Investigational
S-8510
S-8510 / SB-737552 is a BZD inverse agonist investigated for the treatment of Alzheimer’s disease and mild to moderate senile dementia. It was being codeveloped by Shionogi and GlaxoSmithKline.
Investigational
Matched Description: … S-8510 / SB-737552 is a BZD inverse agonist investigated for the treatment of Alzheimer’s disease and …
Sulfotep
Experimental
Vet approved
Vixarelimab
Vixarelimab is under investigation in clinical trial NCT03816891 (A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Prurigo Nodularis).
Investigational
Matched Description: … Vixarelimab is under investigation in clinical trial NCT03816891 (A Study to Assess the Efficacy, Safety …
99mTc-HYNIC (Tyr3)-octreotide
Investigational
XL820
XL820 is investigated for use/treatment in solid tumors. XL820 is a solid. The proteins that XL820 inhibit include platelet-derived growth factor receptor beta (PDGFR), mast/stem cell growth factor receptor KIT, vascular endothelial growth factor receptor 2, and platelet-derived growth factor receptor alpha, clinically validated targets implicated in a variety of...
Investigational
Matched Description: … XL820 is a solid. ... receptor 2, and platelet-derived growth factor receptor alpha, clinically validated targets implicated in a …
Sparteine
Sparteine is a plant alkaloid derived from Cytisus scoparius and Lupinus mutabilis which may chelate calcium and magnesium. It is a sodium channel blocker, so it falls in the category of class 1a antiarrhythmic agents. Sparteine is not currently FDA-approved for human use, and its salt, sparteine sulfate, is one...
Experimental
Withdrawn
Matched Description: … It is a sodium channel blocker, so it falls in the category of class 1a antiarrhythmic agents. ... Sparteine is a plant alkaloid derived from _Cytisus scoparius_ and _Lupinus mutabilis_ which may chelate …
Cirazoline
Cirazoline acts on a number of α adrenergic receptors. It is an agonist of α1A, partial agonist of α1B and α1D, and a nonselective antagonist of α2. It is believed that this combination of properties could make cirazoline an effective vasoconstricting agent.
Cirazoline has also been shown to decrease food...
Experimental
Matched Description: … Cirazoline acts on a number of α adrenergic receptors. ... It is an agonist of α1A, partial agonist of α1B and α1D, and a nonselective antagonist of α2. …
SCB-2019
SCB-2019 is a recombinant trimeric S protein subunit vaccine candidate being investigated against COVID-19. This vaccine candidate resembles the native trimeric viral spike and is produced through mammalian cell-culture.
The vaccine was developed and tested by Clover Biopharmaceuticals AUS Pty Ltd.. As of June 2020, the company is pursuing a...
Investigational
Matched Description: … SCB-2019 is a recombinant trimeric S protein subunit vaccine candidate being investigated against COVID ... As of June 2020, the company is pursuing a randomized, double blind, placebo controlled study (NCT04405908 …
Displaying drugs 11176 - 11200 of 11952 in total